Literature DB >> 9470868

Patterns and costs of hospital care for coronary heart disease related and not related to diabetes.

C J Currie1, C L Morgan, J R Peters.   

Abstract

OBJECTIVE: To describe the epidemiology and costs of coronary heart disease (CHD) requiring hospital admission, with particular reference to diabetes.
SETTING: The former South Glamorgan Health Authority, South Wales.
METHODS: Routine hospital activity data were record linked and all diabetic and non-diabetic individuals over a four year period (1991-95) were identified. A cost weight was included for each admission based on diagnosis related groups.
RESULTS: There were 10,214 patients admitted with a primary diagnostic code for CHD, representing an incidence of 6.3 per 1000 per annum. Including all CHD and non-CHD admissions, these individuals were responsible for 17% of acute inpatient activity. Men had a consistently higher age specific prevalence of CHD than women. The age adjusted relative risk of CHD for patients with diabetes compared with those without was 4.1 for men and 5.5 for women. Patients with diabetes accounted for 16.9% of CHD related admissions and had a fourfold increased probability of undergoing a cardiac procedure. The total cost of CHD was estimated to be 6% of NHS revenue at 1994-95 pay and prices. Patients with diabetes were responsible for 16% of this expenditure. This translated to an estimated NHS acute hospital expenditure for CHD of 1.1 billion pounds per year at 1994-95 pay and prices.
CONCLUSIONS: CHD was responsible for a larger proportion of NHS expenditure than had previously been reported. Nearly one in five acute hospital admissions were for patients whose condition included cardiac problems. The relation between diabetes and CHD was particularly evident, and may offer opportunities for disease prevention.

Entities:  

Mesh:

Year:  1997        PMID: 9470868      PMCID: PMC1892321          DOI: 10.1136/hrt.78.6.544

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Sex and coronary heart disease: the relative probability of dying in hospital.

Authors:  C J Currie; J R Peters
Journal:  Heart       Date:  1997-04       Impact factor: 5.994

2.  Differences in hospital casemix, and the relationship between casemix and hospital costs.

Authors:  N Söderlund; R Milne; A Gray; J Raftery
Journal:  J Public Health Med       Date:  1995-03

3.  Coronary artery surgery: are women discriminated against?

Authors:  M Petticrew; M McKee; J Jones
Journal:  BMJ       Date:  1993-05-01

4.  Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

Authors:  W B Kannel
Journal:  Am Heart J       Date:  1985-11       Impact factor: 4.749

5.  Computerised linking of medical records: methodological guidelines.

Authors:  L Gill; M Goldacre; H Simmons; G Bettley; M Griffith
Journal:  J Epidemiol Community Health       Date:  1993-08       Impact factor: 3.710

6.  Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study.

Authors:  E L Barrett-Connor; B A Cohn; D L Wingard; S L Edelstein
Journal:  JAMA       Date:  1991-02-06       Impact factor: 56.272

7.  Patterns of in and out-patient activity for diabetes: a district survey.

Authors:  C J Currie; D R Williams; J R Peters
Journal:  Diabet Med       Date:  1996-03       Impact factor: 4.359

8.  Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria.

Authors:  S L Jones; C F Close; M B Mattock; R J Jarrett; H Keen; G C Viberti
Journal:  BMJ       Date:  1989-02-25

9.  Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus.

Authors:  A S Krolewski; E J Kosinski; J H Warram; O S Leland; E J Busick; A C Asmal; L I Rand; A R Christlieb; R F Bradley; C R Kahn
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

10.  Glycated haemoglobin and metabolic control of diabetes mellitus: external versus locally established clinical targets for primary care.

Authors:  C Butler; J Peters; N Stott
Journal:  BMJ       Date:  1995-03-25
  10 in total
  10 in total

1.  Diagnostic accuracy of technician supervised and reported exercise tolerance tests.

Authors:  D F Muir; M Jummun; D J Stewart; A L Clark
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

Review 2.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 3.  Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement.

Authors:  M Pringle
Journal:  BMJ       Date:  1998-10-24

4.  Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.

Authors:  M Jones; P McEwan; C Ll Morgan; J R Peters; J Goodfellow; C J Currie
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

Review 5.  Epidemiology in diabetes mellitus and cardiovascular disease.

Authors:  Wenjun Fan
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

6.  Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin.

Authors:  C J Currie; M Jones; J Goodfellow; P McEwan; C L Morgan; C Emmas; J R Peters
Journal:  Heart       Date:  2005-05-09       Impact factor: 5.994

7.  The economic burden of coronary heart disease in the UK.

Authors:  J L Y Liu; N Maniadakis; A Gray; M Rayner
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

8.  A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.

Authors:  Nigel Buller; David Gillen; Roman Casciano; John Doyle; Koo Wilson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis.

Authors:  Elise M Pelletier; Boyung Shim; Rami Ben-Joseph; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  GCK gene-body hypomethylation is associated with the risk of coronary heart disease.

Authors:  Limin Xu; Dawei Zheng; Lingyan Wang; Danjie Jiang; Haibo Liu; Leiting Xu; Qi Liao; Lina Zhang; Panpan Liu; Xinbao Shi; Zhaoyang Wang; Lebo Sun; Qingyun Zhou; Ni Li; Yi Huang; Yanping Le; Meng Ye; Guofeng Shao; Shiwei Duan
Journal:  Biomed Res Int       Date:  2014-02-17       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.